Overview Dividends

(CME) CME - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US12572Q1058

Futures, Options, Swaps, Clearing, Data

Financial Exchanges & Data
Market Cap in USD: 97,034m
IPO / Inception: 2002-12-06
Return 12m vs S&P 500: 4.02%

EPS (Earnings per Share)

EPS (Earnings per Share) of CME over the last years for every Quarter: "2020-12": 1.39, "2021-03": 1.79, "2021-06": 1.64, "2021-09": 1.6, "2021-12": 1.66, "2022-03": 2.11, "2022-06": 1.97, "2022-09": 1.98, "2022-12": 1.92, "2023-03": 2.42, "2023-06": 2.3, "2023-09": 2.25, "2023-12": 2.37, "2024-03": 2.5, "2024-06": 2.56, "2024-09": 2.68, "2024-12": 2.52, "2025-03": 2.8, "2025-06": 2.96, "2025-09": 2.68,
EPS CAGR: 13.62%
EPS Trend: 89.1%
Last SUE: 1.21
Qual. Beats: 1

Revenue

Revenue of CME over the last years for every Quarter: 2020-12: 1098.5, 2021-03: 1253.3, 2021-06: 1179.2, 2021-09: 1109.9, 2021-12: 1147.3, 2022-03: 1346.6, 2022-06: 1237.2, 2022-09: 1227.8, 2022-12: 1207.8, 2023-03: 1441.6, 2023-06: 1360.2, 2023-09: 1337.8, 2023-12: 1439.3, 2024-03: 1487.9, 2024-06: 1532.5, 2024-09: 1584.4, 2024-12: 1525.3, 2025-03: 1642.3, 2025-06: 1692, 2025-09: 1537.6,
Rev. CAGR: 8.12%
Rev. Trend: 90.0%
Last SUE: 0.54
Qual. Beats: 0

Dividends

Dividend Yield 1.81%
Yield on Cost 5y 3.35%
Yield CAGR 5y 15.22%
Payout Consistency 93.1%
Payout Ratio 45.6%
Risk via 5d forecast
Volatility 17.4%
Value at Risk 5%th 29.2%
Relative Tail Risk 2.11%
Reward TTM
Sharpe Ratio 0.88
Alpha 18.21
CAGR/Max DD 1.96
Character TTM
Hurst Exponent 0.365
Beta -0.074
Beta Downside -0.030
Drawdowns 3y
Max DD 11.65%
Mean DD 3.62%
Median DD 3.13%

Description: CME CME December 02, 2025

CME Group Inc. (NASDAQ:CME) operates the world’s largest derivatives exchange platform, offering futures and options across interest rates, equity indexes, FX, agricultural commodities, energy, and metals, plus clearing, settlement, and risk-mitigation services for both exchange-traded and cleared-swap products.

Key operational metrics illustrate its market dominance: in 2023 the firm generated ≈ $5.5 billion in net revenue, processed over 30 billion contracts through its clearinghouse, and holds roughly 50 % market share in U.S. interest-rate futures-a segment that reacts sharply to Federal Reserve policy cycles.

Sector-level drivers that materially affect CME’s topline include (1) central-bank rate moves, which boost trading volume in Treasury-linked futures; (2) commodity price volatility, especially in energy and agricultural markets, which fuels demand for hedging instruments; and (3) the ongoing migration of institutional trading to electronic platforms, enhancing CME’s data-service revenue streams.

For a deeper, data-driven view of CME’s valuation dynamics, a quick look at ValueRay’s analyst toolkit can surface the quantitative levers most likely to move the stock price.

Piotroski VR‑10 (Strict, 0-10) 3.5

Net Income (3.75b TTM) > 0 and > 6% of Revenue (6% = 383.8m TTM)
FCFTA 0.02 (>2.0%) and ΔFCFTA -0.45pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 50.23% (prev 38.40%; Δ 11.83pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA 0.02 (>3.0%) and CFO 4.16b > Net Income 3.75b (YES >=105%, WARN >=100%)
Net Debt (968.0m) to EBITDA (5.35b) ratio: 0.18 <= 3.0 (WARN <= 3.5)
Current Ratio 1.02 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (360.3m) change vs 12m ago 0.09% (target <= -2.0% for YES)
Gross Margin 86.14% (prev 86.06%; Δ 0.08pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 3.94% (prev 4.39%; Δ -0.45pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio 29.45 (EBITDA TTM 5.35b / Interest Expense TTM 170.4m) >= 6 (WARN >= 3)

Altman Z'' 0.46

(A) 0.02 = (Total Current Assets 152.80b - Total Current Liabilities 149.59b) / Total Assets 187.14b
(B) 0.03 = Retained Earnings (Balance) 5.71b / Total Assets 187.14b
(C) 0.03 = EBIT TTM 5.02b / Avg Total Assets 162.47b
(D) 0.04 = Book Value of Equity 5.75b / Total Liabilities 158.95b
Total Rating: 0.46 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 84.15

1. Piotroski 3.50pt
2. FCF Yield 4.17%
3. FCF Margin 63.84%
4. Debt/Equity 0.12
5. Debt/Ebitda 0.18
6. ROIC - WACC (= 7.00)%
7. RoE 13.71%
8. Rev. Trend 89.99%
9. EPS Trend 89.11%

What is the price of CME shares?

As of December 28, 2025, the stock is trading at USD 276.73 with a total of 545,877 shares traded.
Over the past week, the price has changed by +2.84%, over one month by -1.02%, over three months by +2.86% and over the past year by +20.82%.

Is CME a buy, sell or hold?

CME has received a consensus analysts rating of 3.39. Therefor, it is recommend to hold CME.
  • Strong Buy: 4
  • Buy: 3
  • Hold: 7
  • Sell: 4
  • Strong Sell: 0

What are the forecasts/targets for the CME price?

Issuer Target Up/Down from current
Wallstreet Target Price 286.7 3.6%
Analysts Target Price 286.7 3.6%
ValueRay Target Price 327.3 18.3%

CME Fundamental Data Overview December 23, 2025

Market Cap USD = 97.03b (97.03b USD * 1.0 USD.USD)
P/E Trailing = 26.0494
P/E Forward = 23.0947
P/S = 15.1967
P/B = 3.4421
P/EG = 5.6661
Beta = 0.293
Revenue TTM = 6.40b USD
EBIT TTM = 5.02b USD
EBITDA TTM = 5.35b USD
Long Term Debt = 3.42b USD (from longTermDebt, last quarter)
Short Term Debt = 749.8m USD (from shortTermDebt, last fiscal year)
Debt = 3.42b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 968.0m USD (from netDebt column, last quarter)
Enterprise Value = 97.88b USD (97.03b + Debt 3.42b - CCE 2.58b)
Interest Coverage Ratio = 29.45 (Ebit TTM 5.02b / Interest Expense TTM 170.4m)
FCF Yield = 4.17% (FCF TTM 4.08b / Enterprise Value 97.88b)
FCF Margin = 63.84% (FCF TTM 4.08b / Revenue TTM 6.40b)
Net Margin = 58.64% (Net Income TTM 3.75b / Revenue TTM 6.40b)
Gross Margin = 86.14% ((Revenue TTM 6.40b - Cost of Revenue TTM 886.7m) / Revenue TTM)
Gross Margin QoQ = 84.55% (prev 86.90%)
Tobins Q-Ratio = 0.52 (Enterprise Value 97.88b / Total Assets 187.14b)
Interest Expense / Debt = 1.29% (Interest Expense 44.0m / Debt 3.42b)
Taxrate = 22.85% (269.0m / 1.18b)
NOPAT = 3.87b (EBIT 5.02b * (1 - 22.85%))
Current Ratio = 1.02 (Total Current Assets 152.80b / Total Current Liabilities 149.59b)
Debt / Equity = 0.12 (Debt 3.42b / totalStockholderEquity, last quarter 28.19b)
Debt / EBITDA = 0.18 (Net Debt 968.0m / EBITDA 5.35b)
Debt / FCF = 0.24 (Net Debt 968.0m / FCF TTM 4.08b)
Total Stockholder Equity = 27.36b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.00% (Net Income 3.75b / Total Assets 187.14b)
RoE = 13.71% (Net Income TTM 3.75b / Total Stockholder Equity 27.36b)
RoCE = 16.30% (EBIT 5.02b / Capital Employed (Equity 27.36b + L.T.Debt 3.42b))
RoIC = 12.58% (NOPAT 3.87b / Invested Capital 30.78b)
WACC = 5.58% (E(97.03b)/V(100.46b) * Re(5.74%) + D(3.42b)/V(100.46b) * Rd(1.29%) * (1-Tc(0.23)))
Discount Rate = 5.74% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 100.0 | Cagr: 0.09%
[DCF Debug] Terminal Value 79.84% ; FCFE base≈3.90b ; Y1≈4.37b ; Y5≈5.81b
Fair Price DCF = 279.2 (DCF Value 100.69b / Shares Outstanding 360.6m; 5y FCF grow 13.81% → 3.0% )
EPS Correlation: 89.11 | EPS CAGR: 13.62% | SUE: 1.21 | # QB: 1
Revenue Correlation: 89.99 | Revenue CAGR: 8.12% | SUE: 0.54 | # QB: 0
EPS next Quarter (2026-03-31): EPS=2.91 | Chg30d=+0.017 | Revisions Net=+1 | Analysts=11
EPS next Year (2026-12-31): EPS=11.66 | Chg30d=+0.049 | Revisions Net=+6 | Growth EPS=+4.4% | Growth Revenue=+4.5%

Additional Sources for CME Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle